To screen for senolytic drugs that enhance the growth inhibitory effects of everolimus and gemcitabine, we treated malignant meningioma cells with senolytic drugs, such as OTX015, an inhibitor of bromodomain and extra-terminal proteins [22]; quercetin and dasatinib [23]; navitoclax, an inhibitor of anti-apoptotic BCL-2 family proteins [10,24,25]; geldanamycin, an inhibitor of heat shock protein 90 [26]; and BPTES, an inhibitor of glutaminase 1 [27], in combination with everolimus and gemcitabine. Here, BCL2 is linked to meningioma.